[THE INVESTOR] On Sept. 27, Daihan Pharm (023910) declined 0.99% to 30,000 won (US$27.31). It had declined 3.88% through the past month. Standard deviation, which indicates volatility of stock, records 2.2% over the same period over one month.

Compared with its close competitors within the same industry, KOSDAQ, even though the monthly earnings rate of Daihan Pharm stayed negative, its volatility for one month was at the lowest level. Over the recent month, the return-on-risk, the return on investment with consideration about risk, was -1.7%. As the volatility was low, the return-on-risk was a proper rate in spite of stock price decline. However, compared with the KOSDAQ industry, the return-on-risk is below the industrial mean, -0.1, and thus it is hard to say that the industrial comparison performance was positive.

From Sept. 23, foreigners have been continuously buying Daihan Pharm during the past two trading days. As a shareholding sum by investor group for the past four weeks, foreigners have bought 70,852 shares with a maintenance of shareholding and Individuals have bought 62,875 shares with an increasing position. However, during the same period, institutions have sold 133,727 shares with a selling trend.

Cumulated shareholdings per investor group (1Mo) Total shareholdings per investor group

By HeRo (hero@heraldcorp.com)

This article is produced by the algorithm developed by the artificial intelligence developer ThinkPool in collaboration with Herald Corp.